Journal of Christian Religious Studies

Regenerative medicine has transformed modern healthcare by providing innovative approaches for repairing, replacing, and regenerating damaged tissues and organs through stem cell therapy, tissue engineering, and cloning technologies. While these advances offer promising treatment options for chronic and degenerative diseases, they also raise important ethical, legal, religious, and social concerns, particularly regarding embryo use, human dignity, cloning, informed consent, commercialization of biological materials, and equitable access to emerging therapies. This study examined the ethical implications of regenerative medicine with emphasis on stem cell research, cloning technologies, and moral responsibility. A qualitative explanatory research design was adopted, employing documentary analysis and scholarly literature review. Data were obtained from peer-reviewed journal articles, books, policy documents, bioethical guidelines, and reports published by international organizations and analyzed using thematic content analysis. The study was underpinned by Principlism Theory, which emphasizes the ethical principles of autonomy, beneficence, non-maleficence, and justice, alongside relevant religious and philosophical perspectives. The findings indicate that regenerative medicine has considerable potential to improve healthcare through disease treatment, tissue regeneration, and enhanced quality of life. However, significant ethical concerns relating to embryo destruction, human cloning, identity, personhood, and equitable access to emerging therapies persist. The study concludes that scientific advancement in regenerative medicine should be guided by robust ethical governance, effective regulatory oversight, and respect for human dignity. It recommends strengthening ethical review and regulatory frameworks for regenerative medicine research and promoting continuous bioethics education and interdisciplinary collaboration among researchers, healthcare professionals, policymakers, and other stakeholders to ensure the responsible and socially beneficial advancement of biomedical innovation.

Open Full Text (PDF)